GlassScriptPhysician profile
James M Mwatibo
NPI 1710975487
$7,490.07
in general payments reported to CMS, 2019-2025
41 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $1,112 · 2021: $1,448 · 2022: $1,070 · 2023: $1,025 · 2024: $874 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,020.51 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $924.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $650.71 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $606.48 | 2020-2025 | |
| Pfizer INC. | $562.23 | 2019-2025 | |
| Allergan, INC. | $414.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.12 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Amarin Pharma, INC. | $361.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $334.91 | 2021-2023 | |
| Ardelyx, INC. | $223.37 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $196.02 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $195.67 | 2022-2023 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $187.59 | 2019-2021 | |
| Abbott Laboratories | $168.99 | 2022-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $139.86 | 2023 | Quviviq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $128.92 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $119.04 | 2023 | Micra |
| Dexcom, INC. | $98.25 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $75.74 | 2019-2024 | Repatha, Otezla |
| Eisai INC. | $70.74 | 2021 | |
| Sanofi Pasteur INC. | $69.61 | 2019-2021 | |
| Astellas Pharma US INC | $66.57 | 2022-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $63.22 | 2022-2025 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $62.78 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $37.51 | 2022-2023 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $28.89 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $28.42 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2019-2022 | |
| Kyowa Kirin, INC. | $24.55 | 2025 | |
| Edwards Lifesciences Corporation | $22.61 | 2024 | |
| Glaxosmithkline, LLC. | $21.40 | 2024 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $21.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $19.54 | 2025 | Capvaxive |
| Biogen, INC. | $17.05 | 2024 | Skyclarys |
| Silk Road Medical, INC. | $16.25 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Global Blood Therapeutics, INC. | $16.22 | 2020 | |
| Zyla Life Sciences, INC. | $16.05 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.44 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.78 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mwatibo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.